Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07675174 · ClinicalTrials.gov registry record · Phase 1
Phase I-II PTCy, Bortezomib and Sitagliptin for Prevention of GvHD Following Allogeneic HSCT
A Phase 1 study, sponsored by Northwell Health.
- Not yet
- Registry status
- Phase 1
- Development phase
- 72
- Enrollment target
NCT07675174 is a Phase 1 study that has not yet begun recruiting, run by Northwell Health. The registered enrollment target is 72 participants.
The verdict
NCT07675174, a Phase 1 study, has not yet begun recruiting, sponsored by Northwell Health.
- NOT YET RECRUITING
- Registry status
- Phase 1
- Development phase
- 72 participants
- Enrollment target
Study Summary
Phase I-II studying post transplant cyclophosphamide, bortezomib and sitagliptin for GvHD prevention in allogeneic HSCT. Adults with hematologic malignancies undergoing an RIC allogeneic PBSC transplant from a 5/6 or 6/6 sibling or 7/8 or 8/8 matched unrelated donor.
Interventions
- DRUG Post transplant cyclophosphamide, bortezomib and sitagliptin in 3+3 design to MTD
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2026-07-01 |
| Est. Completion | 2032-07-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07675174
The ClinicalTrials.gov registry entry for NCT07675174 describes a study currently listed as not yet recruiting, categorized as Phase 1. The registered enrollment target is 72 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Northwell Health, which has 370 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Post transplant cyclophosphamide, bortezomib and sitagliptin in 3+3 design to MTD is the first listed.
NCT07675174 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07675174 about?
NCT07675174 is a clinical study titled "Phase I-II PTCy, Bortezomib and Sitagliptin for Prevention of GvHD Following Allogeneic HSCT". Phase I-II studying post transplant cyclophosphamide, bortezomib and sitagliptin for GvHD prevention in allogeneic HSCT. Adults with hematologic malignancies undergoing an RIC allogeneic PBSC transplant from a 5/6 or 6/6 sibling or 7/8 or 8/8 matched unrelated donor.
What is the current status of trial NCT07675174?
This trial is currently not yet recruiting. It is a Phase 1 study. The enrollment target is 72 participants. The study started on 2026-07-01. Estimated completion is 2032-07-01.
What interventions are being tested in trial NCT07675174?
The interventions under investigation include: Post transplant cyclophosphamide, bortezomib and sitagliptin in 3+3 design to MTD (DRUG).
Who is sponsoring clinical trial NCT07675174?
This trial is sponsored by Northwell Health, which has 370 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.